| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0dfd28b225eea9234cde9e0ffcd28e40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51819a06e0b14071fd1e57e6ff4acfa5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b9ca445465ed3557192f55652045cc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b811a32478e5784d083649d393c8e01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 |
| filingDate |
2008-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ff8574b7008582a5862f26488d5ee78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc3e67b76c55a3e04ef243badfb3dfcd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7a88ae02ed13dd3f8a065fb5dd6af3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_185473fa82f28f54585ef1201f6699ac |
| publicationDate |
2009-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009008694-A1 |
| titleOfInvention |
Pharmaceutical composition comprising the combination of an anti-depressive agent and an ansiolytic agent for control and treatment of depressive disorders |
| abstract |
The present invention concerns a pharmaceutical composition formed by the synergic combination of an anti-depressive selective 5-HT reuptake inhibitor, such as is the active principle: Sertraline and an ansiolytic agent belonging to the triazolobenzodiazepine group, such as is the active principle: Alprazolam, which are formulated in a single dosing unit to be administered by oral means in the form of capsules or tablets, the former being prescribed for the control and treatment of diseases such as: depressive disorders and related pathologies. |
| priorityDate |
2007-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |